{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:56:22Z","timestamp":1787237782347,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atrial flutter with 1:1 conduction to the ventricles is a dangerous cardiac arrhythmia. Contemporary guidelines recommend atrioventricular nodal blocking agents should be co-administered with class 1C anti-arrhythmics, as prophylaxis against 1:1 flutter. No guidance is provided on the type or strength of atrioventricular nodal blockade required, and in practice, these agents are frequently prescribed at low dose, or even omitted, due to their side effect profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 62\u00a0year old  Caucasian man with a history of paroxysmal atrial fibrillation treated with flecainide, presented with atrial flutter with 1:1 conduction to the ventricles and was cardioverted. Diltiazem was added to prevent this complication and he again presented with atrial flutter with 1:1 conduction to the ventricles, despite prophylaxis with coadministration of diltiazem.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case report demonstrates failure of diltiazem to prevent 1:1 flutter in a patient chronically treated with flecainide for paroxysmal atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-023-03947-5","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T10:02:19Z","timestamp":1689674539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"K. D.","family":"Tiver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Quah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-3025","authenticated-orcid":false,"given":"A. N.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"5","key":"3947_CR1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","volume":"167","author":"J Ball","year":"2013","unstructured":"Ball J, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167(5):1807\u201324.","journal-title":"Int J Cardiol"},{"issue":"1","key":"3947_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4\u201320.","journal-title":"Circ Res"},{"issue":"2","key":"3947_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v7.i2.76","volume":"7","author":"GK Andrikopoulos","year":"2015","unstructured":"Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015;7(2):76\u201385.","journal-title":"World J Cardiol"},{"issue":"10","key":"3947_CR4","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/j.1540-8159.1997.tb06117.x","volume":"20","author":"A Capucci","year":"1997","unstructured":"Capucci A, Villani GQ, Aschieri D. Risk of complications of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20(10):2684\u201391.","journal-title":"Pacing Clin Electrophysiol"},{"key":"3947_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4684","volume":"340","author":"R Taylor","year":"2010","unstructured":"Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. BMJ. 2010;340: b4684.","journal-title":"BMJ"},{"issue":"10","key":"3947_CR6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1540-8167.1996.tb00475.x","volume":"7","author":"RWF Campbell","year":"1996","unstructured":"Campbell RWF. Pharmacologic therapy of atrial flutter. J Cardiovasc Electrophysiol. 1996;7(10):1008\u201312.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"10","key":"3947_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.hlc.2018.06.1043","volume":"27","author":"NHFA CSANZ Atrial Fibrillation Guideline Working Group","year":"2018","unstructured":"NHFA CSANZ Atrial Fibrillation Guideline Working Group, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ. 2018;27(10):1209\u201366.","journal-title":"Heart Lung Circ"},{"issue":"2","key":"3947_CR8","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125\u201351.","journal-title":"Circulation"},{"issue":"38","key":"3947_CR9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"issue":"3","key":"3947_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/europace\/eun012","volume":"10","author":"M Kawabata","year":"2008","unstructured":"Kawabata M, et al. Clinical and electrophysiological characteristics of patients having atrial flutter with 1:1 atrioventricular conduction. Europace. 2008;10(3):284\u20138.","journal-title":"Europace"},{"issue":"11","key":"3947_CR11","doi-asserted-by":"publisher","first-page":"2131.e3","DOI":"10.1016\/j.ajem.2018.07.040","volume":"36","author":"I Comelli","year":"2018","unstructured":"Comelli I, Pigna F, Cervellin G. 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. Am J Emerg Med. 2018;36(11):2131.e3-2131.e5.","journal-title":"Am J Emerg Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03947-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03947-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03947-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T10:11:32Z","timestamp":1689675092000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03947-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3947"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03947-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}